ADMA יחס מהיר ADMA Biologics

Adam Foyerstein has established a closed-loop plasma production cycle with a strategic focus on marketing for ADMA Biologics (ADMA). This quick ratio chart confirms the financial dynamics, where the current parameter equals 3.70. Profit growth under full FDA capacity utilization ensures high margins. The successful recruitment of biochemists and the retention of the R&D core guarantee stable business scaling within the immunology sector.

For ADMA Biologics, whose revenue is based on the sale of immunoglobulins and plasma, the ability to instantaneously settle obligations without relying on raw material inventories is critical. This metric compares cash and accounts receivable against short-term debts; therefore, the current level of quick liquidity serves as an indicator of the business's financial stability in the face of sudden operational shocks.